Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.34 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18533846 | 0.86 | MGLL (0.40) | MGLLGMNNALDH1A1LMNAMAPT | |
| SCHEMBL1578819 | 0.82 | MGLL (0.37) | MGLLGMNNALDH1A1LMNAMAPT | |
| SCHEMBL18431250 | 0.78 | MGLL (0.34) | MGLLGMNNALDH1A1LMNAMAPT | |
| SCHEMBL17897015 | 0.78 | MGLL (0.34) | MGLLGMNNALDH1A1LMNAMAPT | |
| SCHEMBL23900402 | 0.78 | MGLL (0.35) | MGLLGMNNALDH1A1LMNAMAPT | |
| SCHEMBL21000173 | 0.78 | MGLL (0.31) | MGLLGMNNALDH1A1LMNAMAPT | |
| SCHEMBL21776243 | 0.77 | MGLL (0.37) | MGLLGMNNALDH1A1LMNAMAPT | |
| SCHEMBL23132261 | 0.77 | MGLL (0.38) | MGLLGMNNALDH1A1LMNAMAPT | |
| SCHEMBL21000176 | 0.76 | ALDH1A1 (0.31) | MGLLGMNNALDH1A1LMNAMAPT | |
| SCHEMBL21000172 | 0.75 | LMNA (0.32) | MGLLGMNNALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2558127-B1 | TARGETED PYRROLOBENZODIAZEPINE CONJUGATES | SEAGEN INC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20200247847-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247847-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | HSD3B2, HSD3B1, HSD11B2 | MGLL 4801/4885GMNN 4833/4885ALDH1A1 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.